Will Summit report interim OS data from HARMONi-3 before the November 14 PDUFA date?

Management guided H2 2026 for final PFS + interim OS. They are acutely aware of the November 14 PDUFA date. It would be strategically irrational to guide H2 2026 if they expected Q4 delivery — they need OS before PDUFA. The squamous cohort enrolled first, giving more time for OS events to mature. However, OS is driven by biology, not corporate timelines.

OS typically requires substantially longer follow-up than PFS. Even with enrollment complete, the squamous cohort events may not mature quickly enough for a meaningful interim analysis. 'H2 2026' is deliberately vague — companies often use broad guidance when timing is uncertain. The question asks about public reporting, which may lag internal data availability by weeks.

Summit may submit interim OS data directly to FDA during the review process without public disclosure. However, the question asks about public reporting. Management has incentive to publicize positive OS data immediately. If OS trends are unfavorable, they may delay. The coin flip reflects genuine uncertainty about timing within H2 2026.

True coin flip. H2 2026 spans July-December; PDUFA is mid-November. If interim OS is ready by September-October, it resolves YES. If November-December, it resolves NO. I have no strong evidence to favor either side. OS maturity is unpredictable and management guidance was deliberately non-specific.

Summit would not have added the interim OS analysis to H2 2026 guidance if they did not expect it before the PDUFA decision. They know the FDA requires OS. Their commercial readiness activities pre-PDUFA suggest confidence in the full data package being available. Weighting management's strategic behavior as informative.

OS data maturity is fundamentally a biological process. Management can influence enrollment and study design but not how quickly patients die. NSCLC squamous has relatively short OS compared to other cancers, which helps. But interim OS requires a pre-specified number of events. Low confidence in timing prediction.

Slightly above 50% because management is aware of PDUFA timing and guided H2 2026. But OS timing is genuinely uncertain. Low confidence.

OS data maturity is hard to predict. H2 2026 is broad. Could easily slip to Q4. PDUFA is in mid-November, leaving a narrow window.

Management would not be ramping commercial readiness if they expected to miss the PDUFA with OS data. They added interim OS to the protocol guidance knowing the timeline constraints. Modest bullish lean.